Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of the administration of a copper chelating agent,
tetrathiomolybdate, for patients with idiopathic pulmonary fibrosis that have failed previous
treatment. The primary endpoint for this study is safety with secondary endpoints including
change in pulmonary function, exercise capacity, and quality of life.